Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GW Pharmaceuticals ready to accelerate childhood epilepsy drug development

GW Pharmaceuticals ready to accelerate childhood epilepsy drug development

GW Pharmaceuticals (LON:GWP) told investors its lead epilepsy product candidate has the potential to meet significant unmet needs in childhood epilepsy, and the US$101mln it raised recently it can accelerate the programme.

It raised the cash through the issue of ADS shares on the NASDAQ exchange this month, and it is to be ploughed into the Epidiolex development programme.

Epidiolex has a US Food & Drug Administration (FDA) orphan drug designation for the treatment of Dravet syndrome (a type of childhood epilepsy), and approval has been granted for a programme to treat 125 children.

Treatment is now beginning in this programme, and initial data is expected by mid-2014.

Other programmes are ongoing and will provide findings this year also.

In the meantime work continues on the Sativex drug, with separate Phase 3 trials ongoing for cancer pain and MS. Also following recent approvals, the Sativex drug has now been approved in 25 countries.

“With the new funds raised, we have the financial strength to accelerate this development program whilst retaining global commercial rights," said chief executive Justin Gover.

"In addition to our orphan epilepsy programme, as we move through 2014, we expect a significant amount of milestones, including Phase 3 cancer pain data for Sativex as well as important clinical progress across our robust pipeline of cannabinoid product candidates."

Revenues in three months to December 31 were £7.5mln, up from £5.2mln in the same period of the prior year, and the group made a £2.8mln loss, versus a £2.1mln profit in the three months to December 31 2012.

View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
1528098797_Biotech-lab.jpg
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use